Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer

(2011) E. M. Fox et al.   CANCER RESEARCH

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer

(2010) J. N. Ingle et al.   CANCER RESEARCH

Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?

(2010) Amna Sheri et al.   Clinical Breast Cancer

Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis

(2010) Priscilla F. McAuliffe et al.   Clinical Breast Cancer

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy

(2010) B. C. Litzenburger et al.   CLINICAL CANCER RESEARCH

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

(2010) Todd W. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Enhancing the Efficacy of Hormonal Agents with Selected Targeted Agents

(2009) Stephen R.D. Johnston   Clinical Breast Cancer

Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial

(2009) Emanuela Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

(2008) Matthew J. Sikora et al.   BREAST CANCER RESEARCH AND TREATMENT

Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer

(2008) J. Michael Dixon et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer

(2008) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

27-Hydroxycholesterol Is an Endogenous Selective Estrogen Receptor Modulator

(2007) Carolyn D. DuSell et al.   MOLECULAR ENDOCRINOLOGY